Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands.
Department of Internal Medicine, Gerontology and Geriatrics Section, Leiden University Medical Center, Leiden, Netherlands.
J Clin Endocrinol Metab. 2018 Oct 1;103(10):3658-3667. doi: 10.1210/jc.2018-00481.
Anemia and thyroid dysfunction often co-occur, and both increase with age. Human data on relationships between thyroid disease and anemia are scarce.
To investigate the cross-sectional and longitudinal associations between clinical thyroid status and anemia.
Individual participant data meta-analysis.
Sixteen cohorts participating in the Thyroid Studies Collaboration (n = 42,162).
Primary outcome measure was anemia (hemoglobin <130 g/L in men and <120 g/L in women).
Cross-sectionally, participants with abnormal thyroid status had an increased risk of having anemia compared with euthyroid participants [overt hypothyroidism, pooled OR 1.84 (95% CI 1.35 to 2.50), subclinical hypothyroidism 1.21 (1.02 to 1.43), subclinical hyperthyroidism 1.27 (1.03 to 1.57), and overt hyperthyroidism 1.69 (1.00 to 2.87)]. Hemoglobin levels were lower in all groups compared with participants with euthyroidism. In the longitudinal analyses (n = 25,466 from 14 cohorts), the pooled hazard ratio for the risk of development of anemia was 1.38 (95% CI 0.86 to 2.20) for overt hypothyroidism, 1.18 (1.00 to 1.38) for subclinical hypothyroidism, 1.15 (0.94 to 1.42) for subclinical hyperthyroidism, and 1.47 (0.91 to 2.38) for overt hyperthyroidism. Sensitivity analyses excluding thyroid medication or high levels of C-reactive protein yielded similar results. No differences in mean annual change in hemoglobin levels were observed between the thyroid hormone status groups.
Higher odds of having anemia were observed in participants with both hypothyroid function and hyperthyroid function. In addition, reduced thyroid function at baseline showed a trend of increased risk of developing anemia during follow-up. It remains to be assessed in a randomized controlled trial whether treatment is effective in reducing anemia.
贫血和甲状腺功能障碍常同时发生,且随年龄增长而增加。关于甲状腺疾病与贫血之间关系的人体数据较为匮乏。
研究临床甲状腺功能与贫血之间的横断面和纵向关联。
个体参与者数据荟萃分析。
参加甲状腺研究协作组的 16 个队列(n=42162)。
主要观察指标为贫血(男性血红蛋白<130 g/L,女性血红蛋白<120 g/L)。
在横断面分析中,与甲状腺功能正常的参与者相比,甲状腺功能异常的参与者发生贫血的风险增加[显性甲状腺功能减退症,汇总 OR 1.84(95%CI 1.35 至 2.50),亚临床甲状腺功能减退症 1.21(1.02 至 1.43),亚临床甲状腺功能亢进症 1.27(1.03 至 1.57),显性甲状腺功能亢进症 1.69(1.00 至 2.87)]。与甲状腺功能正常的参与者相比,所有组的血红蛋白水平均较低。在纵向分析(14 个队列中的 25466 名参与者)中,显性甲状腺功能减退症的贫血发生风险的汇总危险比为 1.38(95%CI 0.86 至 2.20),亚临床甲状腺功能减退症为 1.18(1.00 至 1.38),亚临床甲状腺功能亢进症为 1.15(0.94 至 1.42),显性甲状腺功能亢进症为 1.47(0.91 至 2.38)。排除甲状腺药物或 C 反应蛋白水平较高的敏感性分析得出了类似的结果。在甲状腺激素状态组之间,血红蛋白水平的年平均变化无差异。
甲状腺功能减退和甲状腺功能亢进的参与者发生贫血的几率更高。此外,基线时甲状腺功能降低与随访期间贫血发生风险增加呈趋势相关。在随机对照试验中,是否治疗有效降低贫血仍有待评估。